Health TidingsOno Leverages Congruence Revenir™ for Neurology, Immunology Breakthroughs Ono Leverages Congruence Revenir™ for Neurology, Immunology Breakthroughs Read Post »
Health TidingsAtara and Pierre Fabre Seek FDA Type A Meeting to Advance Tab-Cel After CRL Atara and Pierre Fabre Seek FDA Type A Meeting to Advance Tab-Cel After CRL Read Post »
Health TidingsFDA Grants Rare Public Hearing on Vanda’s HETLIOZ® Jet Lag Approval ... FDA Grants Rare Public Hearing on Vanda’s HETLIOZ® Jet Lag Approval ... Read Post »
Policy & AcquisitionsCullgen Joins Gyre in $300M Pact, Boosting Protein Degraders Cullgen Joins Gyre in $300M Pact, Boosting Protein Degraders Read Post »
Clinical TrailsMerck, Eisai Advance Dual Oral Therapy with Strong Phase 3 RCC Data at ASCO... Merck, Eisai Advance Dual Oral Therapy with Strong Phase 3 RCC Data at ASCO... Read Post »
Health TidingsPhase 3 Setback for Aardvark’s ARD-101 as HERO Enrollment Freezes Phase 3 Setback for Aardvark’s ARD-101 as HERO Enrollment Freezes Read Post »
Clinical Trails55% Risk Reduction: Ralinepag’s ADVANCE OUTCOMES Results Signal New P... 55% Risk Reduction: Ralinepag’s ADVANCE OUTCOMES Results Signal New P... Read Post »
New Drug ApprovalHERNEXEOS® Gains FDA Nod as First-Line Option for HER2-Mutant NSCLC HERNEXEOS® Gains FDA Nod as First-Line Option for HER2-Mutant NSCLC Read Post »
Health TidingsIntellia Gains Complete FDA Greenlight for Nex-z ATTR Trials Post-Hold Reso... Intellia Gains Complete FDA Greenlight for Nex-z ATTR Trials Post-Hold Reso... Read Post »
Health TidingsJohnson & Johnson Unveils Promising Phase 1b Data for Pasritamig Plus D... Johnson & Johnson Unveils Promising Phase 1b Data for Pasritamig Plus D... Read Post »
New Drug ApprovalFDA Approves Once-Weekly YUVIWEL® for Pediatric Achondroplasia FDA Approves Once-Weekly YUVIWEL® for Pediatric Achondroplasia Read Post »
Clinical TrailsAbbVie’s SKYRIZI Shows Strong Induction Results in Hard-to-Treat Crohn’... AbbVie’s SKYRIZI Shows Strong Induction Results in Hard-to-Treat Crohn’... Read Post »
Health TidingsHuntington’s Hope Dims? FDA Urges Sham-Controlled Trial for uniQure AMT-1... Huntington’s Hope Dims? FDA Urges Sham-Controlled Trial for uniQure AMT-1... Read Post »
Health TidingsRoche Fenebrutinib Phase III Success: 51% Fewer MS Relapses Roche Fenebrutinib Phase III Success: 51% Fewer MS Relapses Read Post »
Clinical TrailsMerck Reports Positive Phase 3 Results Across Ovarian, Bladder, and Renal C... Merck Reports Positive Phase 3 Results Across Ovarian, Bladder, and Renal C... Read Post »
Health TidingsFDA Accepts BLA for Imsidolimab: A Precision Therapy Poised to Transform Ge... FDA Accepts BLA for Imsidolimab: A Precision Therapy Poised to Transform Ge... Read Post »
Clinical TrailsSystImmune and BMS Report Dual PFS/OS Wins for Iza-Bren in Advanced TNBC Ph... SystImmune and BMS Report Dual PFS/OS Wins for Iza-Bren in Advanced TNBC Ph... Read Post »
Clinical TrailsOrganon Highlights VTAMA Family Sleep Benefits in ADORING Trials Organon Highlights VTAMA Family Sleep Benefits in ADORING Trials Read Post »
Health TidingsOno Pharmaceutical Ends Forxiga Partnership with AstraZeneca in Japan Ono Pharmaceutical Ends Forxiga Partnership with AstraZeneca in Japan Read Post »
Lifestyle WellnessMelatonin for Better Sleep: Mechanisms and Evidence from Clinical Trials Melatonin for Better Sleep: Mechanisms and Evidence from Clinical Trials Read Post »
Health TidingsFDA Grants Priority Review to Ionis’ Olezarsen for Severe Hypertrigly... FDA Grants Priority Review to Ionis’ Olezarsen for Severe Hypertrigly... Read Post »
Health TidingsEMA CHMP Backs Moderna’s mCOMBRIAX®: Pioneering Flu-COVID Combo Vacc... EMA CHMP Backs Moderna’s mCOMBRIAX®: Pioneering Flu-COVID Combo Vacc... Read Post »
Clinical TrailsLilly’s Olumiant Shows Strong Hair Regrowth in Adolescents with Sever... Lilly’s Olumiant Shows Strong Hair Regrowth in Adolescents with Sever... Read Post »
Health Tidings Policy & AcquisitionsNovartis Finalizes $12B Avidity Buyout for AOC Muscle Tech Novartis Finalizes $12B Avidity Buyout for AOC Muscle Tech Read Post »
New Drug ApprovalFDA Approves BioMarin PALYNZIQ for Adolescents with PKU FDA Approves BioMarin PALYNZIQ for Adolescents with PKU Read Post »
Clinical TrailsBayer’s PEACE‑3 Phase III Trial Shows Enzalutamide Plus Radium‑223 Im... Bayer’s PEACE‑3 Phase III Trial Shows Enzalutamide Plus Radium‑223 Im... Read Post »
Health Tidings Policy & AcquisitionsEarendil Labs Secures $885M WuXiTecan-2 Rights from WuXi XDC Earendil Labs Secures $885M WuXiTecan-2 Rights from WuXi XDC Read Post »
Health TidingsCHMP Backs Single-Dose Acoziborole to End Gambiense Sleeping Sickness Era CHMP Backs Single-Dose Acoziborole to End Gambiense Sleeping Sickness Era Read Post »
Health Tidings Policy & AcquisitionsExclusive: Boehringer Ingelheim Acquires Sitryx Program in High-Value Autoi... Exclusive: Boehringer Ingelheim Acquires Sitryx Program in High-Value Autoi... Read Post »
Health TidingsGilead’s Bictegravir/Lenacapavir FDC Shows Week 48 Promise in ARTISTR... Gilead’s Bictegravir/Lenacapavir FDC Shows Week 48 Promise in ARTISTR... Read Post »
Clinical TrailsGalderma’s Nemluvio Shows Sustained Efficacy and Safety in Prurigo No... Galderma’s Nemluvio Shows Sustained Efficacy and Safety in Prurigo No... Read Post »
Health TidingsViiV Healthcare Unveils Promising Phase 1 Data for Two Ultra Long-Acting HI... ViiV Healthcare Unveils Promising Phase 1 Data for Two Ultra Long-Acting HI... Read Post »
Clinical TrailsPalvella Announces Topline Win for QTORIN in Microcystic Lymphatic Malforma... Palvella Announces Topline Win for QTORIN in Microcystic Lymphatic Malforma... Read Post »
Clinical TrailsArgenx Reports Improved Ocular Symptoms in MG with Subcutaneous VYVGART Argenx Reports Improved Ocular Symptoms in MG with Subcutaneous VYVGART Read Post »
Health TidingsGSK’s Bepirovirsen NDA Accepted in Japan for Chronic Hepatitis B GSK’s Bepirovirsen NDA Accepted in Japan for Chronic Hepatitis B Read Post »
Clinical TrailsEli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 ... Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 ... Read Post »
New Drug ApprovalJ&J Seeks FDA Approval of IMAAVY® as First Treatment for wAIHA J&J Seeks FDA Approval of IMAAVY® as First Treatment for wAIHA Read Post »
Health TidingsGSK’s Linerixibat Gains NMPA Priority Review in China for Itch in Rar... GSK’s Linerixibat Gains NMPA Priority Review in China for Itch in Rar... Read Post »
Clinical TrailsViiV’s Lotivibart Hits 94% HIV Control at 12 Months EMBRACE Data ViiV’s Lotivibart Hits 94% HIV Control at 12 Months EMBRACE Data Read Post »
Clinical TrailsAxsome Therapeutics Doses First Patient in CLARITY Phase 3 Trial Axsome Therapeutics Doses First Patient in CLARITY Phase 3 Trial Read Post »
Health Tidings Policy & AcquisitionsBeam Therapeutics Advances BEAM-304 for PKU and Pfizer Collaboration Beam Therapeutics Advances BEAM-304 for PKU and Pfizer Collaboration Read Post »
Health Tidings Policy & AcquisitionsNovo Nordisk Partners with Vivtex to Pioneer Oral Biologics for Obesity and... Novo Nordisk Partners with Vivtex to Pioneer Oral Biologics for Obesity and... Read Post »
Health Tidings Policy & AcquisitionsGSK Acquires 35Pharma for $950M to Advance HS235 in Pulmonary Hypertension ... GSK Acquires 35Pharma for $950M to Advance HS235 in Pulmonary Hypertension ... Read Post »
Clinical TrailsPromising Phase 3 Data for Merck’s Doravirine/Islatravir Combo in HIV Promising Phase 3 Data for Merck’s Doravirine/Islatravir Combo in HIV Read Post »
Drugs Safety AlertFDA Halts New Enrollment in MacroGenics’ Lorigerlimab Trial Over Safe... FDA Halts New Enrollment in MacroGenics’ Lorigerlimab Trial Over Safe... Read Post »
Clinical TrailsBristol Myers Squibb’s Reblozyl Shows Promise in Alpha-Thalassemia: P... Bristol Myers Squibb’s Reblozyl Shows Promise in Alpha-Thalassemia: P... Read Post »
Health TidingsViatris Phentolamine Drops Advance to FDA Review for Presbyopia Treatment Viatris Phentolamine Drops Advance to FDA Review for Presbyopia Treatment Read Post »
New Drug ApprovalFDA Grants Full Approval to Pfizer’s BRAFTOVI Regimen FDA Grants Full Approval to Pfizer’s BRAFTOVI Regimen Read Post »
Health TidingsOno Expands Opdivo® Reach: New Korean Approval for MSI-High CRC Ono Expands Opdivo® Reach: New Korean Approval for MSI-High CRC Read Post »
New Drug ApprovalDupixent Approved by FDA: Sanofi & Regeneron’s First Treatment fo... Dupixent Approved by FDA: Sanofi & Regeneron’s First Treatment fo... Read Post »
